Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Core Insights - Aclarion, Inc. has appointed Jason Brosniak as Commercial Director for the Eastern U.S. to enhance the adoption of its Nociscan technology [1][3] - Brosniak brings over 20 years of experience in MedTech, having previously worked with companies like Relievant Medsystems and Kyphon, which positions him well to drive growth in the spine and pain management sectors [2][3] - The demand for Nociscan is increasing due to real-world evidence trials and the national CLARITY randomized controlled trial, highlighting the need for additional commercial resources in the Eastern U.S. [3] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to help physicians differentiate between painful and nonpainful discs [4] - Nociscan is the first evidence-supported SaaS platform that noninvasively quantifies chemical biomarkers associated with disc pain, providing critical insights for treatment optimization [4] - The company aims to expand access to its technology for the estimated 266 million people globally suffering from chronic low back pain [3]